Cargando…

OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult females

This 24-week double-blind placebo-controlled multicenter randomized phase 2 trial evaluated efficacy and safety of onabotulinumtoxinA (onabotA; BOTOX) vs. placebo for major depressive disorder (MDD) [NCT02116361]. Primary endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS);...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brin, Mitchell F., Durgam, Suresh, Lum, Arlene, James, Lynn, Liu, Jeen, Thase, Michael E., Szegedi, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams And Wilkins 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6903360/ https://www.ncbi.nlm.nih.gov/pubmed/31609787 http://dx.doi.org/10.1097/YIC.0000000000000290

Ejemplares similares

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
por: Winner, Paul K., et al.
Publicado: (2020)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

Safety of OnabotulinumtoxinA with Concomitant Antithrombotic Therapy in Patients with Muscle Spasticity: A Retrospective Pooled Analysis of Randomized Double-Blind Studies
por: Dimitrova, Rozalina, et al.
Publicado: (2020)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Jankovic, Joseph, et al.
Publicado: (2023)

Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Scott, Alan B., et al.
Publicado: (2023)

Treatment of glabellar lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Jean, et al.
Publicado: (2023)

Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double‐blind, placebo‐controlled study
por: Durgam, Suresh, et al.
Publicado: (2019)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia
por: Marsh, Wallace A, et al.
Publicado: (2014)

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial
por: Durgam, Suresh, et al.
Publicado: (2018)

Repeated OnabotulinumtoxinA Treatment of Glabellar Lines at Rest Over Three Treatment Cycles
por: Carruthers, Alastair, et al.
Publicado: (2016)

Entering the 4(th) decade of Botox (onabotulinumtoxinA): A narrative review of its development and impact on patients and medicine
por: Brin, Mitchell F.
Publicado: (2023)

Treatment of crow’s feet lines and forehead lines with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Carruthers, Alastair, et al.
Publicado: (2023)

Pooled analysis of the safety and tolerability of onabotulinumtoxinA in the treatment of chronic migraine
por: Diener, H-C, et al.
Publicado: (2014)

OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction – A Randomized, Double-Blind, Placebo-Controlled Study
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

Efficacy and safety of onabotulinumtoxinA with standardized occupational therapy for treatment of pediatric upper limb spasticity: Phase III placebo-controlled randomized trial
por: Dimitrova, Rozalina, et al.
Publicado: (2021)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Gormley, Mark, et al.
Publicado: (2023)

OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients
por: Gfrerer, Lisa, et al.
Publicado: (2021)

Safety and Stability of Pulmonary Function in Patients with Decreased Respiratory Function Treated for Spasticity with OnabotulinumtoxinA
por: Ayyoub, Ziyad, et al.
Publicado: (2020)

Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
por: Matharu, Manjit, et al.
Publicado: (2017)

Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial
por: Devier, Deidre, et al.
Publicado: (2017)

Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trials
por: Thase, Michael E., et al.
Publicado: (2017)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
por: Winner, Paul K., et al.
Publicado: (2019)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Efficacy and safety of onabotulinumtoxinA with standardized physiotherapy for the treatment of pediatric lower limb spasticity: A randomized, placebo-controlled, phase III clinical trial
por: Dimitrova, Rozalina, et al.
Publicado: (2022)

A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, FIXED-DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
por: Gommoll, Carl, et al.
Publicado: (2015)

Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment: A Cumulative 29-Year Safety Update
por: Brin, Mitchell F., et al.
Publicado: (2023)

A Prospective, Nonrandomized, Open‐Label Study of the Efficacy and Safety of OnabotulinumtoxinA in Adolescents with Primary Axillary Hyperhidrosis
por: Glaser, Dee Anna, et al.
Publicado: (2015)

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
por: Clayton, Anita H., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_slcqa0n290rkbbat5784ceg2vf